[
    [
        {
            "time": "",
            "original_text": "智飞生物召开新冠疫苗Ⅲ期临床数据研讨会 对任何严重程度保护效力约82%",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "Ⅲ期临床",
                    "保护效力",
                    "82%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物召开新冠疫苗Ⅲ期临床数据研讨会 对任何严重程度保护效力约82%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "智飞生物新冠疫苗研讨会消息，正推进免疫程序优化、二代疫苗研究",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "研讨会",
                    "免疫程序优化",
                    "二代疫苗"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物新冠疫苗研讨会消息，正推进免疫程序优化、二代疫苗研究",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：重组新型冠状病毒疫苗（CHO细胞）学术研讨会近日召开",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新型冠状病毒疫苗",
                    "CHO细胞",
                    "学术研讨会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：重组新型冠状病毒疫苗（CHO细胞）学术研讨会近日召开",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]